VivoSeq
Cardiovascular

Portal Hypertension

36

Pipeline Programs↗

16

Active Trials↗

20

Companies Involved↗

Portal Hypertension is a moderately active landscape with 36 programs across 20 companies. The most active players are Ferring, Conatus Pharmaceuticals Inc., Novartis. 8 therapies are approved with 8 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

90/100

Attrition Rate

4/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Ferring logo

Ferring

1 program

Phase 1C

Conatus Pharmaceuticals Inc.

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 2G

Galectin Therapeutics Inc.

1 program

Phase 2S

Sucampo Pharma Americas, LLC

1 program

Phase 2C

Cumberland Pharmaceuticals

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical8

Fentanyl

Cephalon

Sonovue

Bracco Diagnostics, Inc

Perflutren Lipid Microspheres

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Peginterferon Alpha-2a

Johnson & Johnson

Terlipressin

Mallinckrodt

Phase 11

FE 999301

Ferring

Phase 211

Metformin

EMD Serono

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Cadonilimab

Shanghai Pharmaceuticals Holding Co., Ltd

Donafenib

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

IDN-6556

Conatus Pharmaceuticals Inc.

Phase 38

Somatostatin

Johnson & Johnson

Propranolol

Wyeth-Lederle Vaccines

Rivaroxaban

Wim Janssens

Rosuvastatin

AstraZeneca

Apixaban

Bristol-Myers Squibb

Approved8

Simvastatin

Organon and Co

Sorafenib

Bayer

Carvedilol

Akero Therapeutics

Entecavir

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Anti-Obesity Pharmacotherapy (class Effect)

The Cleveland Clinic

Analysis

Modality Breakdown

93%

Small molecule

41 of 44 classified programs — the dominant modality here.

7%ALL OTHERSPeptide25%Monoclonal antibody12%

Small molecule leads; the ring shows all 44 classified programs, each share of the total. Modality classified for 100% of 45 pipeline programs.

Analysis

Trial Status

54

clinical trials

Completed19 · 35%
Unknown status17 · 31%
Recruiting7 · 13%
Not yet recruiting6 · 11%
Terminated2 · 4%
Active, not recruiting2 · 4%
Other1 · 2%

Clinical Trials

Trial Activity

54 trials

Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Recruiting·TThe Cleveland Clinic·Phase 4·NCT07058155·70 enrolled
SHAPE of Portal Hypertension in Children
Recruiting·TThomas Jefferson University·Phase 2·NCT04720456·120 enrolled
Effects of Metformin on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal Hypertension
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06687265·76 enrolled
Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension
Recruiting·MMayo Clinic·N/A·NCT06797193·60 enrolled
Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension; Renewal
Recruiting·TThomas Jefferson University·Phase 3·NCT05470205·660 enrolled
TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension
Recruiting·—·Phase 2·NCT06646198·40 enrolled
TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study
Recruiting·—·Phase 2·NCT05882370·30 enrolled
Improvement of Portal Hypertension During Viral Suppression in Patients With Hepatitis Delta (IMPHROVE-D)
Active, not recruiting·HHannover Medical School·N/A·NCT04863703·11 enrolled
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04007289·166 enrolled
Liver Cirrhosis Complicated by Clinically Significant Portal Hypertension
Not yet recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07365709·107 enrolled
The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
Not yet recruiting·SShanghai Changzheng Hospital·Phase 2/3·NCT06470386·178 enrolled
TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
Not yet recruiting·TTongji Hospital·Phase 2·NCT07350070·78 enrolled
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
Not yet recruiting·UUniversity Hospital, Tours·Phase 3·NCT06263816·290 enrolled
The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension
Not yet recruiting·SShanghai Changzheng Hospital·Phase 2/3·NCT06473493·30 enrolled
Carvedilol and Alverine in Portal Hypertension
Not yet recruiting·SShanghai Changzheng Hospital·Phase 2/3·NCT06696248·30 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)